A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators

[1]  V. Gurewich,et al.  A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-pro-urokinase: Evidence that t-PA has a more restricted mode of action , 1992 .

[2]  E. Topol,et al.  Clot-selective coronary thrombolysis with lowdose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator☆ , 1991 .

[3]  Jian-ning Liu,et al.  A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. , 1991, The Journal of clinical investigation.

[4]  E. Angles-cano,et al.  Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. , 1991, Biochemistry.

[5]  S. Husain,et al.  Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. , 1991, Biochemistry.

[6]  P. Declerck,et al.  Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma , 1991, Thrombosis and Haemostasis.

[7]  D. Rouy,et al.  The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin. , 1990, The Biochemical journal.

[8]  B. Sobel,et al.  The Nature of Synergy between Tissue-Type and Single Chain Urokinase-Type Plasminogen Activators , 1989, Thrombosis and Haemostasis.

[9]  D. Collen,et al.  The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. , 1989, Blood.

[10]  D. Collen,et al.  Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits , 1989 .

[11]  H. Gold,et al.  Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. , 1989, Circulation.

[12]  M. Samama,et al.  Thrombolytic properties of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (scu-PA) in vitro: Absence of synergy as demonstrated by two quantitative analytical methods , 1989 .

[13]  L. Lund,et al.  One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. , 1988, The Journal of biological chemistry.

[14]  F. Castellino,et al.  The activation of human [Glu1]plasminogen by human single-chain urokinase , 1988 .

[15]  V. Gurewich,et al.  Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. , 1988, The Journal of clinical investigation.

[16]  M. Scully,et al.  Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. , 1987, The Journal of biological chemistry.

[17]  D. Collen,et al.  Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. , 1987, The American journal of cardiology.

[18]  V. Gurewich,et al.  Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). , 1987, Blood.

[19]  V. Gurewich,et al.  A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. , 1986, Thrombosis research.

[20]  M. Verstraete,et al.  Synergism of thrombolytic agents in vivo. , 1986, Circulation.

[21]  D. Collen,et al.  Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro , 1986, Thrombosis and Haemostasis.

[22]  V. Gurewich,et al.  Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. , 1986, Blood.

[23]  E. Angles-cano,et al.  A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. , 1986, Analytical biochemistry.

[24]  M. Hoylaerts,et al.  Activation of plasminogen by pro-urokinase. II. Kinetics. , 1986, The Journal of biological chemistry.

[25]  M. Blaber,et al.  Activation of plasminogen by pro-urokinase. I. Mechanism. , 1986, The Journal of biological chemistry.

[26]  D. Collen,et al.  Activation of Plasminogen by Pro-urokinase , 1986 .

[27]  D. Collen,et al.  A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. , 1985, The Journal of biological chemistry.

[28]  W. Nieuwenhuizen,et al.  A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-containing fragments and not reacting with free fibrinopeptide A. , 1985, Blood.

[29]  D. Collen,et al.  Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology , 1984, Thrombosis and Haemostasis.

[30]  M. Blaber,et al.  Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – III. Thrombolytic Properties of Natural and Recombinant Urokinase in Rabbits with Experimental Jugular Vein Thrombosis , 1984, Thrombosis and Haemostasis.

[31]  V. Gurewich,et al.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. , 1984, The Journal of clinical investigation.

[32]  S. Thorsen,et al.  Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. , 1984, European journal of biochemistry.

[33]  S. Husain,et al.  Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. , 1983, Archives of biochemistry and biophysics.

[34]  W. Schleuning,et al.  Isolation and characterization of urokinase from human plasma. , 1982, The Journal of biological chemistry.

[35]  K. Robbins,et al.  [30] Human plasmin , 1981 .

[36]  B. Wiman,et al.  Molecular mechanism of physiological fibrinolysis , 1978, Nature.

[37]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[38]  B. Wiman,et al.  Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. , 1972, Biochimica et biophysica acta.

[39]  D. Deutsch,et al.  Plasminogen: Purification from Human Plasma by Affinity Chromatography , 1970, Science.

[40]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.